BioMarin Pharma (BMRN) Tops Q2 EPS by 8c, Affirms FY Revenue Guidance, Lowers R&D Expense Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. JNJ
3. AAPL
4. META
5. NRIX
6. SUNS
7. CRDO
8. OIG
9. AMAT
10. SPY

Go back to BioMarin Pharma (BMRN) Tops Q2 EPS by 8c, Affirms FY Revenue Guidance, Lowers R&D Expense Guidance

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $126 at SunTrust Robinson Humphrey

August 3, 2018 2:32 PM EDT

SunTrust Robinson Humphrey raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $126.00 (from $121.00) while maintaining a Buy rating.

Analyst Edward Nash commented, "BioMarin reported a strong 2nd quarter. All but Kuvan's net product sales beat Street consensus. Prior guidance... More

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Stifel

August 3, 2018 9:36 AM EDT

Stifel raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $109.00 (from $102.00) while maintaining a Buy rating.

... More

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $98 at Barclays

August 3, 2018 5:06 AM EDT

Barclays raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $98.00 (from $95.00) while maintaining a Equalweight rating.

... More